- 01High cholesterol is really a problem of particle count
What damages arteries is how many apoB-carrying particles push into the artery wall, and for how many years. Total cholesterol blends unrelated fractions into one figure, so apoB or non-HDL cholesterol reads your true risk better than the total-cholesterol number most people watch. Two people can share the same total cholesterol and carry very different particle counts, and it is the count that drives plaque.
If a lab report flagged your cholesterol as high, it means you carry more cholesterol-packed particles in your blood than is healthy for your heart over the long run. What matters is not one reading on one morning but the number of those particles working their way into your artery walls, year after year. High cholesterol causes no symptoms while this happens, which is why a number on a lab report, not how you feel, is what flags it.
What the numbers on your cholesterol panel mean
A standard lipid panel reports a handful of numbers. Each one describes a different piece of how cholesterol and fat travel through your blood inside particles. Here is the plain-language version of each; for the full read of how they interact and what a lab flags, see how to read your lipid panel.
| Number | What it measures | In plain terms |
|---|---|---|
| Total cholesterol | All cholesterol carried in your blood | A sum that blends protective and harmful fractions, which is why it hides more than it shows |
| LDL-C | Cholesterol inside LDL particles | The main atherogenic fraction, usually calculated rather than measured directly |
| HDL-C | Cholesterol inside HDL particles | Higher is generally better, and it is not a treatment target on its own |
| Triglycerides | Fat carried in the blood | Rises with sugar, alcohol, and insulin resistance |
| Non-HDL-C | Total cholesterol minus HDL-C | Captures every atherogenic particle in a single number |
| apoB | A direct count of atherogenic particles | The truest single read of how many risk-carrying particles you have |
For the detail behind any one line, see the marker pages for LDL cholesterol, non-HDL cholesterol, triglycerides, and apolipoprotein B. One practical note: LDL-C on most panels is not measured but estimated from an equation, and that estimate gets unreliable when triglycerides are high or LDL is very low, which is one reason apoB or non-HDL is used as a check.2
The numbers your lipid panel implies
Enter three values, read LDL, non-HDL, and your ratio. Nothing leaves your browser.
Why total cholesterol is the least useful number
Total cholesterol adds together things that pull in opposite directions: the atherogenic particles that build plaque and the protective HDL that does not. Two people can post an identical total cholesterol and face very different risk, because the total says nothing about how many harmful particles are in the mix. The evidence that these particles cause disease is about as settled as cardiology gets.
Low-density lipoproteins cause atherosclerotic cardiovascular disease.Ference BA et al., EAS Consensus Panel, European Heart Journal, 2017
Risk depends on both how many atherogenic particles you carry and how long they act on your arteries. That is why particle count, read by apoB or by non-HDL cholesterol, is a truer risk signal than the cholesterol cargo those particles carry.5 A small dense particle and a large fluffy one each count as one particle that can lodge in a wall.
Every atherogenic particle carries exactly one apoB, so apoB counts the particles that can lodge in an artery wall, not the cholesterol riding inside them.
The cumulative part is the point. Lowering the particle burden earlier and keeping it lower for longer bends the whole curve, which is why a number that looks unremarkable today can still be doing quiet damage.
What counts as 'high'?
There is no single line that makes cholesterol 'high' for everyone. Labs flag values against population reference ranges, but the level a clinician acts on drops as your overall cardiovascular risk rises: someone who already has heart disease or diabetes is guided toward a lower LDL than a low-risk adult with no other risk factors.1 The tiers below are common US reference points in mg/dL, and intermediate bands sit between the columns; for LDL, 100 to 129 mg/dL is often called 'near optimal.'
| Number (mg/dL) | Desirable | Borderline | High |
|---|---|---|---|
| LDL-C | Under 100 | 130 to 159 | 160 and up (190+ is very high) |
| Non-HDL-C | Under 130 | 160 to 189 | 190 and up |
| Total cholesterol | Under 200 | 200 to 239 | 240 and up |
| Triglycerides | Under 150 | 150 to 199 | 200 and up (500+ raises pancreatitis risk) |
| HDL-C | 50+ (women), 40+ (men) | not applicable | Under 40 is a risk marker |
What causes high cholesterol?
High cholesterol usually comes from a mix of what you inherit and how you live, not a single cause. The common drivers are genetics, a diet high in saturated fat, excess body weight, physical inactivity, insulin resistance, an underactive thyroid, and some medications.1
- Genetics, including familial hypercholesterolemia and inherited Lp(a)
- A diet high in saturated fat and refined carbohydrate
- Excess body weight and low physical activity
- Insulin resistance and type 2 diabetes, which especially raise triglycerides
- Untreated hypothyroidism (an underactive thyroid)
- Some medications and, for a period, pregnancy
Genetics: familial hypercholesterolemia and Lp(a)
Some people inherit high cholesterol directly. Familial hypercholesterolemia (FH), a genetic condition that keeps LDL high from birth, affects roughly 1 in 250 adults and drives very high LDL and early heart disease if untreated.1 A separate inherited particle, lipoprotein(a) or Lp(a), raises risk on top of your LDL and does not show up on a standard panel at all.
Lp(a) is set by your genes and barely moves with diet, exercise, or statins. You inherit your number and keep it for life.
Because Lp(a) is stable across life, guidelines suggest measuring it once to reveal whether you carry this hidden inherited risk. About one in five people do, and a standard cholesterol panel never shows it.6 See lipoprotein(a) for how to read that number and its unit trap.
Diet, weight, and insulin resistance
Diet moves cholesterol, though less dramatically than genetics. Saturated fat tends to raise LDL, while soluble fiber, from oats, beans, and fruit, modestly lowers it; this is the grain of truth behind the popular idea that oatmeal helps. Insulin resistance and excess weight push triglycerides up and HDL down, a pattern that often travels with a high particle count even when LDL-C looks only moderately raised. The triglyceride-to-HDL ratio is one rough window on that metabolic picture.
Your cholesterol ratios, in context
Two ratios that say more than any single number. Nothing leaves your browser.

When triglycerides run high, ordinary LDL-C underestimates the harmful load carried in triglyceride-rich remnant cholesterol, which is one more reason a clinician may look at non-HDL or apoB rather than LDL-C alone.
How high cholesterol is managed
Management is a series of decisions made with a clinician, weighed against your overall risk, not a fixed prescription that follows automatically from a number. Lifestyle change is the foundation at every risk level, and medication is added when agreed goals are not met. The classes below are described so you can recognize them; none of this is a recommendation to start, stop, or change any treatment.
| Approach | How it works | Good to know |
|---|---|---|
| Lifestyle (diet, weight, activity, stopping smoking) | Lowers LDL and improves the whole risk picture | The foundation at every risk level, used alone or alongside medication |
| Statins | Reduce the liver's cholesterol production, lowering LDL and apoB | First-line drug class, with the largest outcome-trial evidence base |
| Ezetimibe | Blocks cholesterol absorption in the gut | Often added when a statin alone does not reach the agreed goal |
| PCSK9-targeted agents | Help the liver clear more LDL from the blood | Considered for very high LDL or when other options fall short |
The reason lowering LDL is worth the effort is measurable: pooled trial data show each 1 mmol/L (about 39 mg/dL) reduction in LDL cuts major vascular events by roughly 22%, and the benefit is proportional to how much the LDL actually falls.4 Whether, when, and how to treat is a conversation for you and your clinician.
How it is tested and how often to retest
A lipid panel is a routine blood draw, often bundled into a general checkup and typically inexpensive or covered by insurance in the US. Fasting was once standard, but non-fasting panels are now accepted for most screening; if triglycerides are the focus, a clinician may still ask you to fast. If your LDL or non-HDL is unexpectedly high, apoB or Lp(a) may be ordered as separate tests to sharpen the picture.
- Routine screening for most adults is roughly every 4 to 6 years, more often if you have risk factors or are on treatment.
- After a meaningful diet, weight, or medication change, a retest around 6 to 12 weeks later shows the effect.
- If you are diagnosed with familial hypercholesterolemia, cascade screening of first-degree relatives (parents, siblings, children) is recommended, since they each have about a 1-in-2 chance of carrying it.1
- Guidelines suggest checking Lp(a) once in a lifetime, since the level barely changes.6
When high cholesterol needs prompt attention
High cholesterol itself is silent and managed over months and years, not hours. A few situations, though, warrant prompt medical care rather than waiting for the next checkup.
Citations
- Grundy SM, Stone NJ, et al. 2018 AHA/ACC/Multisociety Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143.
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188.
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. EAS Consensus Panel. Eur Heart J. 2017;38(32):2459-2472.
- Cholesterol Treatment Trialists (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
- Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019;4(12):1287-1295.
- Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: an EAS consensus statement. Eur Heart J. 2022;43(39):3925-3946.
- Howard JP, Wood FA, Finegold JA, et al. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment (SAMSON). J Am Coll Cardiol. 2021;78(12):1210-1222.
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.
